GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » ROC %

Pharmaron Beijing Co (HKSE:03759) ROC % : 9.86% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Pharmaron Beijing Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was 9.86%.

As of today (2025-03-29), Pharmaron Beijing Co's WACC % is 15.05%. Pharmaron Beijing Co's ROC % is 8.29% (calculated using TTM income statement data). Pharmaron Beijing Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Pharmaron Beijing Co ROC % Historical Data

The historical data trend for Pharmaron Beijing Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co ROC % Chart

Pharmaron Beijing Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.14 13.86 9.86 9.15 8.16

Pharmaron Beijing Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.06 5.56 7.84 8.10 9.86

Pharmaron Beijing Co ROC % Calculation

Pharmaron Beijing Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=1990.542 * ( 1 - 18.03% )/( (19703.441 + 20291.506)/ 2 )
=1631.6472774/19997.4735
=8.16 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=28959.67 - 2132.175 - ( 7124.054 - max(0, 3997.189 - 11894.203+7124.054))
=19703.441

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=25546.614 - 2260.095 - ( 2995.013 - max(0, 4509.852 - 8123.041+2995.013))
=20291.506

Pharmaron Beijing Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=2754.92 * ( 1 - 26.51% )/( (20769.064 + 20291.506)/ 2 )
=2024.590708/20530.285
=9.86 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=25951.695 - 2322.107 - ( 2860.524 - max(0, 4575.994 - 7815.068+2860.524))
=20769.064

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=25546.614 - 2260.095 - ( 2995.013 - max(0, 4509.852 - 8123.041+2995.013))
=20291.506

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (HKSE:03759) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Pharmaron Beijing Co's WACC % is 15.05%. Pharmaron Beijing Co's ROC % is 8.29% (calculated using TTM income statement data). Pharmaron Beijing Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Pharmaron Beijing Co ROC % Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc 2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd. 2301 Trustee
Kastle Limited 2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you

Pharmaron Beijing Co Headlines

No Headlines